GB9118478D0 — Steroid sulphatase inhibitors
Assigned to Imperial College of London · Expires 1991-10-16 · 35y expired
What this patent protects
The present invention provides a pharmaceutical composition comprising a compound admixed with a pharmaceutically acceptable diluent or carrier; wherein the compound has the the formula wherein each of R<sub>1</sub> and R<sub>2</sub> is independently selec…
USPTO Abstract
The present invention provides a pharmaceutical composition comprising a compound admixed with a pharmaceutically acceptable diluent or carrier; wherein the compound has the the formula wherein each of R<sub>1</sub> and R<sub>2</sub> is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl; and wherein the compound is an inhibitor of an enzyme having steroid sulphatase activity (E.C.3.1.6.2); wherein if the sulphamate group on the compound were to be replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at a pH 7.4 and 37°C it would provide a K<sub>m</sub> value of less than 50 µM; and wherein at least one of R<sub>1</sub> and R<sub>2</sub> is H.
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.